Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour

Breast

Volumn 22, Issue 5, 2013, Pages 986-992

  Elsawaf, Zeinab ^a   Sinn, Hans Peter ^a   Rom, Joachim ^b   Bermejo, Justo Lorenzo ^a   Schneeweiss, Andreas ^b   Aulmann, Sebastian ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; Cluster analysis; Immunohistochemistry; Survival; Triple negative

Indexed keywords

ANTHRACYCLINE; CYTOKERATIN 14; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; TAXANE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BASAL A BREAST CANCER; BASAL B BREAST CANCER; BASOLUMINAL BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER MORPHOLOGY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CLUSTER ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LUMINAL BREAST CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR NECROSIS; UNIVARIATE ANALYSIS;

BREAST CANCER; CLUSTER ANALYSIS; IMMUNOHISTOCHEMISTRY; SURVIVAL; TRIPLE NEGATIVE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; KERATIN-1; KERATIN-14; KERATIN-5; KI-67 ANTIGEN; MIDDLE AGED; NECROSIS; NEOPLASM GRADING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884165276     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.05.012     Document Type: Article

References (30)

1. Morris G.J., Naidu S., Topham A.K., Guiles F., Xu Y., McCue P., et al. Differences in breast carcinoma characteristics in diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007, 110:876-884.
2. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J., et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
3. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
4. Tischkowitz M., Brunet J.S., Begin L.R., Huntsman D.G., Cheang M.C., Akslen L.A., et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7:134.
5. Bowen R.L., Duffy S.W., Ryan D.A., Hart I.R., Jones J.L. Early onset of breast cancer in a group of British black women. Br J Cancer 2008, 98:277-281.
6. Lund M.J., Trivers K.F., Porter P.L., Coates R.J., Leyland-Jones B., Brawley O.W., et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009, 113:357-370.
7. Atchley D.P., Albarracin C.T., Lopez A., Valero V., Amos C.I., Gonzalez-Angulo A.M., et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008, 26:4282-4288.
8. Lakhani S.R., Reis-Filho J.S., Fulford L., Penault-Llorca F., van der Vijver M., Parry S., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180.
9. Fulford L., Reis-Filho J.S., Ryder K., Jones C., Gillett C.E., et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007, 9:R4.
10. Bidard F.C., Conforti R., Boulet T., Michiels S., Delaloge S., Andre F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 2007, 18:1285-1286.
11. Laakso M., Tanner M., Nilsson J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006, 12:4185-4191.
12. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., Habashi H.O., Green A.R., Powe D.G., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15:2302-2310.
13. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28:1145-1153.
14. De Soto J.A., Deng C.X. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?. Int J Med Sci 2006, 3:117-123.
15. Holstege H., Horlings H.M., Velds A., Langerod A., Borresen-Dale A.L., Van de Vijver M.J., et al. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010, 10:654.
16. Rakha E.A., El-Sayed M.E., Reis-Filho J.S., Ellis I.O. Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat 2009, 113:411-422.
17. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
18. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 2784-2795.
19. Eerola H., Heinonen M., Heikkilä P., Kilpivaara O., Tamminen A., Aittomäki K., et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2008, 10:R17.
20. Rakha E.A., El-Rehim D.A., Paish C., Green A.R., Lee A.H., Robertson J.F., et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006, 42:3149-3156.
21. Emig R., Magener A., Ehemann V., Meyer A., Stilgenbauer F., Volkmann M., et al. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 1998, 78:1661-1668.
22. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
23. Rodríguez-Pinilla S.M., Sarrió D., Honrado E., Hardisson D., Calero F., Benitez J., et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006, 12:1533-1539.
24. Kolacinska A., Chalubinska J., Zawlik I., Szymanska B., Borowska-Garganisz E., Nowik M., et al. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer. Neoplasma 2012, 59:424-432.
25. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76.
26. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
27. Lu S., Singh K., Mangray S., Tavares R., Noble L., Resnick M.B., et al. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol 2013, 26:485-495.
28. Fulford L.G., Easton D.F., Reis-Filho J.S., Sofronis A., Gillett C.E., Lakhani S.R., et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006, 49:22-34.
29. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65.
30. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J., Blamey R.W., Robertson J.F., et al. Expression of luminal and basal cytokeratins in human breast carcinoma. JPathol 2004, 203:661-671.